We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone.
- Authors
Alegre, A; Tomás, J F; Martínez-Chamorro, C; Gil-Fernández, J J; Fernández-Villalta, M J; Arranz, R; Díaz, M A; Granda, A; Bernardo, M R; Escudero, A; López-Lorenzo, J L; Fernández-Rañada, J M
- Abstract
The best method for peripheral blood progenitor cell (PBPC) mobilization in patients with multiple myeloma (MM) remains controversial. We report the results of two different methods of PBPC collection for autologous transplantation in 40 patients with stage II or III MM. In group I (n = 18), HD-CY, 4 g/m2 i.v., was administered followed by GM-CSF, 8 μ g/kg/day s.c., until the end of collection, starting the leukaphereses after hematological recovery (>1 × 109/l WBC). In group II (n = 22), G-CSF, 10 μ g/kg/day s.c., was used alone until the last day of collection, starting consecutive aphereses on the 5th day. A minimum of two aphereses were performed to collect at least 2 × 106/kg CD34+ cells. Both patient groups were comparable for age, sex and clinical prognostic features as well as previous therapies. In group I, the median yields per pheresis were: MNC 1.47 (1.38–2.32) × 108/kg, CFU-GM 0.82 (0.18–13.2) × 104/kg and CD34+ cells 1.98 (0.96–6.96) × 106/kg. In group II these results were: MNC 2.44 (2.06–3.6 × 108/kg) (P = 0.03), CFU-GM 0.75 (0.16–7.8) × 104/kg and CD34+ 1.05 (0.32–3.4) × 106/kg (P = 0.02). The median number of aphereses performed in each group was 5 (4–12) with a median of 5.24 ± 2.51 in group I and 3 (2–6) with a median of 3.1 (±0.91) in group II (P = NS). Hospitalization for PBPC mobilization was required in all patients in group I and the treatment-related toxicity was greater in this group: 12 patients (66%) developed fever requiring antibiotics during the neutropenic period after HD-CY and six (33%) patients required transfusion support. After receiving busulfan 12 mg/kg p.o. and melphalan 140 mg/m2 i.v., as the conditioning regimen, the median periods to reach granulocytes (>0.5...
- Subjects
MULTIPLE myeloma; AUTOTRANSPLANTATION
- Publication
Bone Marrow Transplantation, 1997, Vol 20, Issue 3, p211
- ISSN
0268-3369
- Publication type
Article
- DOI
10.1038/sj.bmt.1700867